Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00103558 | Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) | PHASE1 | COMPLETED | 31 | — | — | Mar 1, 2004 | Mar 1, 2010 | Oct 2, 2015 | 5 | United States |
| Name | Type | Description |
|---|---|---|
| Lumiliximab with FCR | DRUG | Dose, schedule, and duration specified in protocol |
Inclusion Criteria: * Age: 18 years and older * Diagnosis of B-cell CLL by International Workshop on CLL (IWCLL) response criteria * Relapsed CD23+ B-cell CLL * Rai Stage III or IV, or Rai Stage I or II if determined to have disease progression as evidenced by rapid doubling or peripheral lymphocyt...